{"id":"edaravone","rwe":[{"pmid":"41889240","year":"2026","title":"Strophioglanes A-E and (±)-Trigoxyphin K, ent-Cleistanthane Diterpenoids from Strophioblachia glandulosa var. cordifolia.","finding":"","journal":"Journal of natural products","studyType":"Clinical Study"},{"pmid":"41866101","year":"2026","title":"Ropivacaine attenuates cerebral ischemia-reperfusion injury in young male mice by reducing endothelial oxidative stress through activation of the Htr7/cAMP-PKA signaling.","finding":"","journal":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","studyType":"Clinical Study"},{"pmid":"41839581","year":"2025","title":"[Effects of acupuncture on ferroptosis and ferritinophagy in cerebral ischemia-reperfusion rats based on KAT3B/ACSL4 pathway].","finding":"","journal":"Zhen ci yan jiu = Acupuncture research","studyType":"Clinical Study"},{"pmid":"41832246","year":"2026","title":"Trial of Edaravone for severe hypoxic ischemic encephalopathy in adults: a double-blind placebo-controlled study.","finding":"","journal":"Journal of neurology","studyType":"Clinical Study"},{"pmid":"41830523","year":"2026","title":"Correction to \"Generalizability of Edaravone Efficacy\".","finding":"","journal":"Muscle & nerve","studyType":"Clinical Study"}],"_fda":{"id":"cfc63132-7290-4b9f-ae4d-29ddf9bcf6b2","set_id":"0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11","openfda":{"upc":["0370510232414","0370510217121","0370510232315"],"unii":["S798V6YJRP"],"route":["INTRAVENOUS"],"rxcui":["1924316","1924317","2602117","2602122"],"spl_id":["cfc63132-7290-4b9f-ae4d-29ddf9bcf6b2"],"brand_name":["RADICAVA","RADICAVA ORS"],"spl_set_id":["0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11"],"package_ndc":["70510-2171-1","70510-2171-2","70510-2321-1","70510-2321-2","70510-2323-1","70510-2322-1","70510-2324-1"],"product_ndc":["70510-2171","70510-2321","70510-2322"],"generic_name":["EDARAVONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["EDARAVONE"],"manufacturer_name":["Shionogi Inc."],"application_number":["NDA209176","NDA215446"],"is_original_packager":[true]},"version":"27","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of RADICAVA or RADICAVA ORS in pregnant women. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. Most of these effects occurred at doses that were also associated with maternal toxicity (see Animal Data ) . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk for major birth defects and miscarriage in patients with ALS is unknown. Data Animal Data In rats, intravenous administration of edaravone (0, 3, 30, or 300 mg/kg/day) throughout the period of organogenesis resulted in reduced fetal weight at all doses. In dams allowed to deliver naturally, offspring weight was reduced at the highest dose tested. Maternal toxicity was also observed at the highest dose tested. There were no adverse effects on reproductive function in the offspring. A no-effect dose for embryofetal developmental toxicity was not identified; the low dose is less than the recommended human dose of 60 mg for RADICAVA on a body surface area (mg/m 2 ) basis. In rabbits, intravenous administration of edaravone (0, 3, 20, or 100 mg/kg/day) throughout the period of organogenesis resulted in embryofetal death at the highest dose tested, which was associated with maternal toxicity. The higher no-effect dose for embryofetal developmental toxicity is approximately 6 times the recommended human dose (RHD) for RADICAVA on a body surface area (mg/m 2 ) basis. The effects on offspring of edaravone (0, 3, 20, or 200 mg/kg/day), administered by intravenous injection to rats from GD 17 throughout lactation, were assessed in two studies. In the first study, offspring mortality was observed at the high dose and increased activity was observed at the mid and high doses. In the second study, there was an increase in stillbirths, offspring mortality, and delayed physical development (vaginal opening) at the highest dose tested. Reproduction function in offspring was not affected in either study. Maternal toxicity was evident in both studies at all but the lowest dose tested. The no-effect dose for developmental toxicity (3 mg/kg/day) is less than the RHD on a mg/m 2 basis. Reproductive and developmental toxicology studies of edaravone using the oral route have not been conducted."],"description":["11 DESCRIPTION The active ingredient in RADICAVA and RADICAVA ORS is edaravone, which is a member of the substituted 2-pyrazolin-5-one class. The chemical name of edaravone is [3-methyl-1-phenyl-2-pyrazolin-5-one]. The molecular formula is C 10 H 10 N 2 O and the molecular weight is 174.20. The chemical structure is: Edaravone is a white crystalline powder with a melting point of 129.7°C. It is freely soluble in acetic acid, methanol, or ethanol and slightly soluble in water or diethyl ether. RADICAVA injection is a clear, colorless liquid provided as a sterile solution. RADICAVA injection is supplied for intravenous infusion in a polypropylene bag containing 30 mg edaravone in 100 mL isotonic, sterile, aqueous solution, which is further overwrapped with polyvinyl alcohol (PVA) secondary packaging. The overwrapped package also contains an oxygen absorber and oxygen indicator to minimize oxidation. Each bag contains the following inactive ingredients: L-cysteine hydrochloride hydrate (10 mg), sodium bisulfite (20 mg). Sodium chloride is added for isotonicity and phosphoric acid and sodium hydroxide are added to adjust to pH 4. RADICAVA ORS (edaravone) oral suspension is a white to off-white color, opaque, homogenous suspension containing 105 mg of edaravone per 5 mL of suspension. RADICAVA ORS contains the following inactive ingredients: L-cysteine hydrochloride hydrate, polyvinyl alcohol, simethicone emulsion, sodium bisulfite, sorbitol, and xanthan gum. Phosphoric acid and sodium hydroxide are added to adjust to pH 4. chemical-structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied RADICAVA RADICAVA is supplied as a 30 mg/100 mL (0.3 mg/mL) clear, colorless, sterile solution for intravenous infusion in single-dose polypropylene bags, each overwrapped with polyvinyl alcohol (PVA) secondary packaging containing an oxygen absorber and oxygen indicator, which should be pink to reflect appropriate oxygen levels [see Dosage and Administration (2.2) and How Supplied/Storage and Handling (16.2) ] . These are supplied in cartons as listed below. NDC 70510-2171-1 30 mg/100 mL (0.3 mg/mL) single-dose bag NDC 70510-2171-2 2 bags per carton RADICAVA ORS RADICAVA ORS is supplied in a white to off-white suspension in multi-dose child resistant 60 mL amber glass bottle which is supplied as two configurations: • RADICAVA ORS Starter Kit (14-day treatment cycle), including two (2) inner cartons, each containing one (1) bottle of 735 mg/35mL (105 mg/5 mL dose), two oral dosing syringes and one bottle adapter. • RADICAVA ORS Kit (10-day treatment cycle), including one (1) bottle of 1050 mg/50 mL (105 mg/5 mL dose) with two oral dosing syringes and one bottle adapter. These are supplied in cartons as listed below: Unit of sale NDC number Package configuration RADICAVA ORS Starter Kit NDC 70510-2321-1 Carton of One (1) bottle of 35mL (105 mg/5 mL dose) NDC 70510-2321-2 Carton of two (2) NDC 70510-2321-1 RADICAVA ORS Kit NDC 70510-2322-1 Carton of One (1) bottle of 50 mL (105 mg/5 mL dose) 16.2 Storage and Handling RADICAVA Store RADICAVA at up to 25°C (77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light. Store in overwrapped package to protect from oxygen degradation until time of use. The oxygen indicator will turn blue or purple if the oxygen has exceeded acceptable levels. Once the overwrap package is opened, use within 24 hours. RADICAVA ORS Pharmacy Store RADICAVA ORS refrigerated between 2ºC to 8ºC (36°F to 46°F) and protect from light. Do not freeze. Store upright. Patient Store RADICAVA ORS upright at room temperature between 20°C to 25°C (68°F to 77°F). Protect from light. Discard 15 days after opening bottle or if unopened 30 days from date of shipment indicated on the carton pharmacy label.","16.1 How Supplied RADICAVA RADICAVA is supplied as a 30 mg/100 mL (0.3 mg/mL) clear, colorless, sterile solution for intravenous infusion in single-dose polypropylene bags, each overwrapped with polyvinyl alcohol (PVA) secondary packaging containing an oxygen absorber and oxygen indicator, which should be pink to reflect appropriate oxygen levels [see Dosage and Administration (2.2) and How Supplied/Storage and Handling (16.2) ] . These are supplied in cartons as listed below. NDC 70510-2171-1 30 mg/100 mL (0.3 mg/mL) single-dose bag NDC 70510-2171-2 2 bags per carton RADICAVA ORS RADICAVA ORS is supplied in a white to off-white suspension in multi-dose child resistant 60 mL amber glass bottle which is supplied as two configurations: • RADICAVA ORS Starter Kit (14-day treatment cycle), including two (2) inner cartons, each containing one (1) bottle of 735 mg/35mL (105 mg/5 mL dose), two oral dosing syringes and one bottle adapter. • RADICAVA ORS Kit (10-day treatment cycle), including one (1) bottle of 1050 mg/50 mL (105 mg/5 mL dose) with two oral dosing syringes and one bottle adapter. These are supplied in cartons as listed below: Unit of sale NDC number Package configuration RADICAVA ORS Starter Kit NDC 70510-2321-1 Carton of One (1) bottle of 35mL (105 mg/5 mL dose) NDC 70510-2321-2 Carton of two (2) NDC 70510-2321-1 RADICAVA ORS Kit NDC 70510-2322-1 Carton of One (1) bottle of 50 mL (105 mg/5 mL dose)"],"geriatric_use":["8.5 Geriatric Use Of the 184 patients with ALS who received RADICAVA in 3 placebo-controlled clinical trials, a total of 53 patients were 65 years of age and older, including 2 patients 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of RADICAVA or RADICAVA ORS in pediatric patients have not been established"],"effective_time":"20260402","clinical_studies":["14 CLINICAL STUDIES The efficacy of RADICAVA ORS is based on a bioavailability study comparing RADICAVA and RADICAVA ORS [see Clinical Pharmacology (12.3) ] . The efficacy of RADICAVA for the treatment of ALS was established in a 6-month, randomized, placebo- controlled, double-blind study conducted in Japanese patients with ALS who were living independently and met the following criteria at screening: 1. Functionality retained most activities of daily living (defined as scores of 2 points or better on each individual item of the ALS Functional Rating Scale – Revised [ALSFRS-R; described below]) 2. Normal respiratory function (defined as percent-predicted forced vital capacity values of [%FVC] ≥80%) 3. Definite or Probable ALS based on El Escorial revised criteria 4. Disease duration of 2 years or less The study enrolled 69 patients in the RADICAVA arm and 68 in the placebo arm. Baseline characteristics were similar between these groups, with over 90% of patients in each group being treated with riluzole. RADICAVA was administered as an intravenous infusion of 60 mg given over a 60-minute period according to the following schedule: • An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period (Cycle 1) • Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (Cycles 2-6). The primary efficacy endpoint was a comparison of the change between treatment arms in the ALSFRS-R total scores from baseline to Week 24. The ALSFRS-R scale consists of 12 questions that evaluate the fine motor, gross motor, bulbar, and respiratory function of patients with ALS (speech, salivation, swallowing, handwriting, cutting food, dressing/hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency). Each item is scored from 0-4, with higher scores representing greater functional ability. The decline in ALSFRS-R scores from baseline was significantly less in the RADICAVA-treated patients as compared to placebo (see Table 3). The distribution of change in ALSFRS-R scores from baseline to Week 24 by percent of patients is shown in Figure 1. Table 3: Analysis of Change from Baseline to Week 24 in ALSFRS-R Scores Treatment Change from Baseline LS Mean ± SE (95% CI) Treatment Difference (RADICAVA – placebo [95% CI]) p -value RADICAVA IV −5.01±0.64 2.49 (0.99, 3.98) 0.0013 Placebo −7.50±0.66 Figure 1 Distribution of Change from Baseline to Week 24 in ALSFRS-R Scores figure-1"],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology At exposures at least 5 times higher than that of the recommended doses of RADICAVA and RADICAVA ORS, edaravone does not prolong the QT interval to any clinically relevant extent."],"pharmacokinetics":["12.3 Pharmacokinetics RADICAVA is administered by IV infusion. The maximum plasma concentration (C max ) of edaravone was reached by the end of infusion. There was a trend of more than dose-proportional increase in area under the concentration-time curve (AUC) and C max of edaravone. With multiple-dose administration, edaravone does not accumulate in plasma. RADICAVA ORS administered orally at the dose of 105 mg, under fasted conditions, was shown to demonstrate an equivalent AUC with RADICAVA (60 mg administered intravenously for 60 min) and C max not less than that of RADICAVA. RADICAVA ORS demonstrated similar pharmacokinetics following administration via feeding tubes and oral administration. In healthy subjects, RADICAVA ORS does not accumulate with once-daily administration, and the maximum plasma concentration (C max ) and area under the concentration-time curve (AUC) of edaravone is more than dose-proportional over the dose range of 30 to 300 mg (approximately 0.3 and 3 times the recommended dosage, respectively). Absorption RADICAVA ORS has a median time to maximum concentration (T max ) occurring at approximately 0.5 hour (range, 0.25 to 0.75 hours) after fasted oral administration. The absolute oral bioavailability is about 57% because of first pass effect when comparing RADICAVA ORS (105 mg oral suspension) and RADICAVA (60 mg intravenous formulation). Effect of Food Following oral administration RADICAVA ORS to healthy subjects 1 hour before or 8 hours after high-fat meals (800-1000 calories, 50% fat), 4 hours after low-fat meals (400-500 calories, 25% fat), or 2 hours after caloric supplement (250 calories, e.g., protein drink), the C max and AUC did not decrease significantly (less than 20% and 10% changes in C max and AUC, respectively) [see Dosage and Administration (2.3) ] . Following oral administration of RADICAVA ORS to healthy subjects, the C max decreased by 82%, and the AUC decreased by 61% with a high-fat meal compared to fasted conditions. Following administration of RADICAVA ORS 4 hours after high-fat meals, the C max and AUC decreased by 44% and 24%, respectively. Following administration of RADICAVA ORS 2 hours after low-fat meals, the C max and AUC decreased by 45% and 21%, respectively. Distribution Edaravone is bound to human serum proteins (92%), mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L. Edaravone has a mean volume of distribution after intravenous administration of 63.1 L. Elimination The mean terminal elimination half-life of edaravone is approximately 4.5 to 9 hours. The half-lives of its metabolites are 3 to 6 hours. Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h. Metabolism Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases. RADICAVA ORS results in 1.3- and 1.7-fold higher exposures for both sulfate and glucuronide metabolites, respectively, when compared to RADICAVA because of first pass metabolism. Excretion In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and < 1% of the dose was recovered in the urine as the unchanged drug. In vitro studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine. Specific Populations Geriatric Patients No age effect on edaravone pharmacokinetics has been found [see Use in Specific Populations (8.5) ]. Patients with Renal Impairment Following single IV infusion of 30 mg edaravone (half the recommended dosage of RADICAVA) over 60 minutes, mean C max and AUC 0-∞ of unchanged edaravone were 1.15- and 1.20-fold greater in the subjects with mild renal impairment (eGFR 60-89 mL/min/1.73m 2 ), and were 1.25- and 1.29-fold greater in the subjects with moderate renal impairment (eGFR 30-59 mL/min/1.73m 2 ) when compared to subjects with normal renal function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with mild to moderate renal impairment. The effects of severe renal impairment on the pharmacokinetics of edaravone have not been studied. Patients with Hepatic Impairment Following single IV infusion of 30 mg edaravone (half of the recommended dose of RADICAVA) over 60 minutes, mean C max and AUC 0-∞ of unchanged edaravone were 1.20- and 1.07-fold greater in the subjects with mild hepatic impairment (Child-Pugh score 5 or 6), were 1.24- and 1.14-fold greater in the subjects with moderate hepatic impairment (Child-Pugh score 7 to 9), and were 1.20- and 1.19-fold greater in the subjects with severe hepatic impairment (Child-Pugh score 10 to 14) when compared to subjects with normal hepatic function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with hepatic impairment. Male and Female Patients No gender effect on edaravone pharmacokinetics has been found. Racial or Ethnic Groups There were no significant racial differences in C max and AUC of edaravone between Japanese and Caucasian subjects. Drug Interaction Studies The pharmacokinetics of edaravone is not expected to be significantly affected by inhibitors of cytochrome P450 (CYP) enzymes, UGTs or major transporters. Concomitant oral administration of edaravone 120 mg (higher than the recommended dose of 105 mg for ORS) with sildenafil (CYP3A4 substrate), rosuvastatin (BCRP substrate), and furosemide (OAT3 substrate) did not produce any changes in C max and AUC of these drugs. In vitro studies demonstrated that, at the recommended dosage, edaravone and its metabolites are not expected to significantly inhibit CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A), conjugating enzymes UGT1A1 and UGT2B7, or other transporters (P-gp, OATP1B1, OATP1B3, OAT1, OCT2, MATE1, and MATE2-K) in humans. Edaravone and its metabolites are not expected to induce CYP1A2, or CYP2B6, at the recommended dosage of edaravone. In vitro data indicated that edaravone was not a substrate of OATP1B1 or OATP1B3."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • Sulfite Allergic Reactions [see Warnings and Precautions (5.2) ] Most common adverse reactions (at least 10% of patients treated with RADICAVA and greater than placebo) are contusion, gait disturbance, and headache ( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In randomized, placebo-controlled trials, 184 patients with ALS were administered RADICAVA 60 mg in treatment cycles for 6 months. The population consisted of Japanese patients who had a median age of 60 years (range 29-75) and were 59% male. Most (93%) of these patients were living independently at the time of screening. Most Common Adverse Reactions Observed During Clinical Studies Table 2 lists the adverse reactions that occurred in ≥ 2% of patients in the RADICAVA-treated group and that occurred at least 2% more frequently than in the placebo-treated group in randomized placebo-controlled ALS trials. The most common adverse reactions that occurred in ≥10% of RADICAVA-treated patients were contusion, gait disturbance, and headache. Table 2: Adverse Reactions from Pooled Placebo-Controlled Trials a that Occurred in ≥2% of RADICAVA -Treated Patients and ≥2% More Frequently than in Placebo Patients Adverse Reaction RADICAVA IV (N=184) % Placebo (N=184) % Contusion 15 9 Gait disturbance 13 9 Headache 10 6 Dermatitis 8 5 Eczema 7 4 Respiratory failure, respiratory disorder, hypoxia 6 4 Glycosuria 4 2 Tinea infection 4 2 a Pooled placebo-controlled studies include two additional studies with 231 additional patients, all using the same treatment regimen [see Clinical Studies (14) ]. Additional Adverse Reactions with RADICAVA ORS In an open-label study in patients with ALS (n=185) treated with RADICAVA ORS for 6 months, fatigue was observed in 7.6% of patients. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of RADICAVA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and subcutaneous tissue disorders: Hypersensitivity reactions and anaphylaxis [see Warnings and Precautions (5.1 , 5.2) ]."],"contraindications":["4 CONTRAINDICATIONS RADICAVA and RADICAVA ORS are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product. Hypersensitivity reactions and anaphylactic reactions have occurred [see Warnings and Precautions (5.1 , 5.2 )]. Patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in RADICAVA and/or RADICAVA ORS ( 4 )"],"how_supplied_table":["
Unit of saleNDC numberPackage configuration
RADICAVA ORS Starter KitNDC 70510-2321-1Carton of One (1) bottle of 35mL (105 mg/5 mL dose)
NDC 70510-2321-2Carton of two (2) NDC 70510-2321-1
RADICAVA ORS KitNDC 70510-2322-1Carton of One (1) bottle of 50 mL (105 mg/5 mL dose)
","
Unit of saleNDC numberPackage configuration
RADICAVA ORS Starter KitNDC 70510-2321-1Carton of One (1) bottle of 35mL (105 mg/5 mL dose)
NDC 70510-2321-2Carton of two (2) NDC 70510-2321-1
RADICAVA ORS KitNDC 70510-2322-1Carton of One (1) bottle of 50 mL (105 mg/5 mL dose)
"],"mechanism_of_action":["12.1 Mechanism of Action The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown."],"instructions_for_use":["Instructions for Use INSTRUCTIONS FOR USE RADICAVA (ra di ká vah) ORS (edaravone) oral suspension Read this Instructions for Use before you take RADICAVA ORS ® for the first time and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Important information about measuring RADICAVA ORS: Always measure your prescribed dose of RADICAVA ORS using the oral syringe provided. Ask your healthcare provider or pharmacist who provided the medicine any questions you have about how to measure your prescribed dose. If you miss a dose, do not take 2 doses of RADICAVA ORS the next day. Do not take a dose of RADICAVA ORS on days 15 through 28. How to prepare RADICAVA ORS : Keep this Instructions for Use handy when preparing the treatment. • If your healthcare provider prescribes a Starter Kit, you will receive 2 bottles of RADICAVA ORS. Each bottle will contain 35 mL of RADICAVA ORS for a total of 70 mL to be used for your first treatment cycle of 14 days. Only open the second bottle when you have finished the first bottle. • If you were not prescribed the Starter Kit, for each treatment cycle you will receive 1 bottle of RADICAVA ORS that contains a total of 50 mL of RADICAVA ORS. After the first treatment cycle, RADICAVA ORS is to be used for 10 days out of 14 day periods. • Only use the bottle adapter and the 2 reusable 5 mL oral syringes provided with the bottle. Do not use a household teaspoon to measure your medicine. How to store RADICAVA ORS: • Store RADICAVA ORS upright at room temperature between 68°F to 77°F (20°C to 25°C). Protect from light. • Opening the bottle: • When you open the bottle of RADICAVA ORS for the first use, write the date you open the bottle on the bottle label. • After opening the bottle of RADICAVA ORS, use within 15 days. • After a bottle of RADICAVA ORS has been opened and used, a white crust may form on the neck or on the side of the bottle. This is due to normal use and RADICAVA ORS can continue to be uses as prescribed. • Keep bottle tightly closed between each use. • Throw away (discard) any RADICAVA ORS that is not used within 15 days after opening the bottle or within 30 days from the date of shipment shown on the carton pharmacy label, whichever happens first. Ask your pharmacist how to properly throw away (discard) RADICAVA ORS you are no longer able to use. • Keep RADICAVA ORS and all medicines out of the reach of children. Each RADICAVA ORS carton contains: • 1 RADICAVA ORS bottle • 1 bottle adapter • 2 (5 mL) reusable oral syringes Use a new 5 mL oral syringe and bottle adapter when using a new bottle of RADICAVA ORS (see Figure A) Figure A Important information: • Keep these instructions for future use. • Do not share RADICAVA ORS with anyone else. • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. • People who have problems using their hands may need assistance to draw up and give the correct dose of RADICAVA ORS. How to take RADICAVA ORS: Take RADICAVA ORS as prescribed by your healthcare provider. Dosing Information: RADICAVA ORS has 2 different dosing schedules: • For the first treatment cycle, you will take RADICAVA ORS every day for 14 days, followed by 14 days without the medicine. • For the cycles after the first treatment cycle, you will take RADICAVA ORS daily for 10 out of 14 days, followed by 14 days without the medicine. How RADICAVA ORS will be provided: • If your healthcare provider prescribes the Starter Kit, you will receive 2 bottles of RADICAVA ORS. Each bottle contains 35 mL of RADICAVA ORS for a total of 70 mL to deliver 14 doses. o There may be some medicine that remains in each bottle after the dose on day 7 and day 14 of the first treatment cycle. Throw away (discard) any medicine that remains. • If you were not prescribed the starter kit, for each treatment cycle, you will receive 1 bottle of RADICAVA ORS that contains a total of 50 mL of RADICAVA ORS to deliver 10 doses. o There may be some medicine that remains in each bottle after 10 doses. Throw away (discard) any medicine that remains. Fasting Information: • Do not eat or drink anything 8 hours before each dose of RADICAVA ORS if you eat a high-fat meal. • Do not eat or drink anything 4 hours before each dose of RADICAVA ORS if you eat a low-fat meal. • Do not eat or drink anything 2 hours before each dose of RADICAVA ORS if you take a calorie supplement. • You should wait at least 1 hour after taking your medicine before eating or drinking anything except water. Step 1: Before each use of RADICAVA ORS: Before opening the bottle, turn it upside down (invert) and shake vigorously up and down for at least 30 seconds (see Figure B). Look at the liquid medicine to make sure it is mixed well. If you see any small pieces at the bottom of the bottle, invert the bottle and shake it up and down for another 30 seconds or until you can no longer see the pieces at the bottom of the bottle (see Figure B). If the liquid medicine all looks the same, you can proceed to Step 2. Shake up and down for at least 30 seconds Figure B Step 2: Open the bottle by firmly pressing down on the bottle cap and turning it counterclockwise (to the left). Place the open bottle upright on a flat surface. Do not throw away the bottle cap; you will need to replace it after taking each dose. First time use of a bottle only. This must only be done 1 time for each bottle. Insert the ribbed end of the bottle adapter into the bottle by firmly pressing it in as far as it will go (see Figure C). Do not remove the bottle adapter. Figure C Step 3: Remove the oral syringe from plastic wrap and make sure the plunger is inserted all the way into the barrel. Push the oral syringe plunger toward its tip to remove excess air (see Figure D). Insert the oral syringe into the opening of the bottle adapter until it is firmly in place (see Figure E). Turn the bottle upside down and slowly pull the plunger to remove a small amount of liquid (see Figure F). Figure D Figure E Figure F Step 4: Keep the bottle upside down and pull the plunger until it goes up to the last line (5 mL) (see Figure G). While keeping the plunger in the same position, turn the bottle upright, and place it carefully on a flat surface. Remove the oral syringe by gently twisting or pulling it out from the bottle (see Figure H). Check the amount of medicine again before moving on to the next step (see Figure I). Note: Do not remove the oral syringe while the bottle is upside down (medicine may leak out through the adapter). Note: If the dose is not correct, insert the oral syringe tip firmly into the bottle adapter. Push the plunger all the way in so that the medicine flows back into the bottle. Turn the bottle upside down. Repeat Step 4. Figure G Figure H Figure I Step 5: Place the tip of the oral syringe in the mouth and aim towards the inside of the cheek. Slowly press down on the plunger until the oral syringe is empty. Swallow all of the medicine (see Figure J). If needed, you can use up to 8 ounces or 1 cup of water to help swallow the medicine. Note: It is normal for a small amount of medicine to remain in the tip of the syringe after taking. Figure J Step 6: Leave the bottle adapter inside the bottle. Place the bottle cap on the bottle and turn the cap clockwise (to the right). Keep bottle tightly closed between each use (see Figure K). Figure K Step 7: Remove the plunger from the oral syringe barrel by pulling the plunger and the barrel away from each other. Rinse the oral syringe (plunger and barrel) with water only . Allow it to air dry. Figure L Step 8: When the oral syringe (plunger and barrel) is dry, put the plunger back into the oral syringe barrel. Do not throw away the oral syringe . Store the syringe in a clean, dry place. You must complete Steps 1 through 4 under \"How to take RADICAVA ORS\" before starting Step 9 under \"How to take a dose of RADICAVA ORS oral suspension through a feeding tube.\" How to take a dose of RADICAVA ORS oral suspension through a feeding tube: Step 9: Using a catheter-tip syringe, flush the feeding tube with 1 ounce (30 mL) of water (see Figure M). Figure M Step 10: Place the oral syringe provided (containing the 5 mL of RADICAVA ORS) into the feeding tube. Slowly push down the plunger until the oral syringe is empty (see Figure N). Figure N Step 11: Using a catheter-tip syringe, flush the feeding tube with 1 ounce (30 mL) of water after taking dose of RADICAVA ORS (see Figure O). Figure O Step 12: Leave the adapter in the bottle. Place the bottle cap on the bottle and turn it clockwise (to the right) to close the bottle. Keep the bottle tightly closed between each use (see Figure P). Figure P Step 13: Remove the plunger from the oral syringe barrel by pulling the plunger and barrel away from each other. Rinse the oral syringe (plunger and barrel) with water only (see Figure Q). Allow it to air dry. Figure Q Step 14: When the oral syringe (plunger and barrel) are dry, put the plunger back into the oral syringe barrel. Do not throw away the oral syringe. Store the oral syringe in a clean, dry place. Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 For more information, go to www.Radicava.com or call 1- 888-292-0058. RADICAVA ORS ® is a registered trademarks of K.K. BCJ-94. © 2025 Tanabe Pharma America, Inc. All rights reserved. This Instructions for Use has been approved by the U.S. Food and Drug Administration. 22022-3 Issued: 12/2025 ifu-figure-a ifu-figure-b ifu-figure-c ifu-figure-d ifu-figure-e ifu-figure-f ifu-figure-g ife-figure-h ifu-figure-i ifu-figure-j ifg-figure-k ifu-figure-l ifu-figure-m ifu-figure-n ifu-figure-o ifu-figure-p ifu-figure-q"],"storage_and_handling":["16.2 Storage and Handling RADICAVA Store RADICAVA at up to 25°C (77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light. Store in overwrapped package to protect from oxygen degradation until time of use. The oxygen indicator will turn blue or purple if the oxygen has exceeded acceptable levels. Once the overwrap package is opened, use within 24 hours. RADICAVA ORS Pharmacy Store RADICAVA ORS refrigerated between 2ºC to 8ºC (36°F to 46°F) and protect from light. Do not freeze. Store upright. Patient Store RADICAVA ORS upright at room temperature between 20°C to 25°C (68°F to 77°F). Protect from light. Discard 15 days after opening bottle or if unopened 30 days from date of shipment indicated on the carton pharmacy label."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At exposures at least 5 times higher than that of the recommended doses of RADICAVA and RADICAVA ORS, edaravone does not prolong the QT interval to any clinically relevant extent. 12.3 Pharmacokinetics RADICAVA is administered by IV infusion. The maximum plasma concentration (C max ) of edaravone was reached by the end of infusion. There was a trend of more than dose-proportional increase in area under the concentration-time curve (AUC) and C max of edaravone. With multiple-dose administration, edaravone does not accumulate in plasma. RADICAVA ORS administered orally at the dose of 105 mg, under fasted conditions, was shown to demonstrate an equivalent AUC with RADICAVA (60 mg administered intravenously for 60 min) and C max not less than that of RADICAVA. RADICAVA ORS demonstrated similar pharmacokinetics following administration via feeding tubes and oral administration. In healthy subjects, RADICAVA ORS does not accumulate with once-daily administration, and the maximum plasma concentration (C max ) and area under the concentration-time curve (AUC) of edaravone is more than dose-proportional over the dose range of 30 to 300 mg (approximately 0.3 and 3 times the recommended dosage, respectively). Absorption RADICAVA ORS has a median time to maximum concentration (T max ) occurring at approximately 0.5 hour (range, 0.25 to 0.75 hours) after fasted oral administration. The absolute oral bioavailability is about 57% because of first pass effect when comparing RADICAVA ORS (105 mg oral suspension) and RADICAVA (60 mg intravenous formulation). Effect of Food Following oral administration RADICAVA ORS to healthy subjects 1 hour before or 8 hours after high-fat meals (800-1000 calories, 50% fat), 4 hours after low-fat meals (400-500 calories, 25% fat), or 2 hours after caloric supplement (250 calories, e.g., protein drink), the C max and AUC did not decrease significantly (less than 20% and 10% changes in C max and AUC, respectively) [see Dosage and Administration (2.3) ] . Following oral administration of RADICAVA ORS to healthy subjects, the C max decreased by 82%, and the AUC decreased by 61% with a high-fat meal compared to fasted conditions. Following administration of RADICAVA ORS 4 hours after high-fat meals, the C max and AUC decreased by 44% and 24%, respectively. Following administration of RADICAVA ORS 2 hours after low-fat meals, the C max and AUC decreased by 45% and 21%, respectively. Distribution Edaravone is bound to human serum proteins (92%), mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L. Edaravone has a mean volume of distribution after intravenous administration of 63.1 L. Elimination The mean terminal elimination half-life of edaravone is approximately 4.5 to 9 hours. The half-lives of its metabolites are 3 to 6 hours. Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h. Metabolism Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases. RADICAVA ORS results in 1.3- and 1.7-fold higher exposures for both sulfate and glucuronide metabolites, respectively, when compared to RADICAVA because of first pass metabolism. Excretion In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and < 1% of the dose was recovered in the urine as the unchanged drug. In vitro studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine. Specific Populations Geriatric Patients No age effect on edaravone pharmacokinetics has been found [see Use in Specific Populations (8.5) ]. Patients with Renal Impairment Following single IV infusion of 30 mg edaravone (half the recommended dosage of RADICAVA) over 60 minutes, mean C max and AUC 0-∞ of unchanged edaravone were 1.15- and 1.20-fold greater in the subjects with mild renal impairment (eGFR 60-89 mL/min/1.73m 2 ), and were 1.25- and 1.29-fold greater in the subjects with moderate renal impairment (eGFR 30-59 mL/min/1.73m 2 ) when compared to subjects with normal renal function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with mild to moderate renal impairment. The effects of severe renal impairment on the pharmacokinetics of edaravone have not been studied. Patients with Hepatic Impairment Following single IV infusion of 30 mg edaravone (half of the recommended dose of RADICAVA) over 60 minutes, mean C max and AUC 0-∞ of unchanged edaravone were 1.20- and 1.07-fold greater in the subjects with mild hepatic impairment (Child-Pugh score 5 or 6), were 1.24- and 1.14-fold greater in the subjects with moderate hepatic impairment (Child-Pugh score 7 to 9), and were 1.20- and 1.19-fold greater in the subjects with severe hepatic impairment (Child-Pugh score 10 to 14) when compared to subjects with normal hepatic function, respectively. These changes in exposures are not considered to be clinically significant and therefore no dosage adjustments are necessary in patients with hepatic impairment. Male and Female Patients No gender effect on edaravone pharmacokinetics has been found. Racial or Ethnic Groups There were no significant racial differences in C max and AUC of edaravone between Japanese and Caucasian subjects. Drug Interaction Studies The pharmacokinetics of edaravone is not expected to be significantly affected by inhibitors of cytochrome P450 (CYP) enzymes, UGTs or major transporters. Concomitant oral administration of edaravone 120 mg (higher than the recommended dose of 105 mg for ORS) with sildenafil (CYP3A4 substrate), rosuvastatin (BCRP substrate), and furosemide (OAT3 substrate) did not produce any changes in C max and AUC of these drugs. In vitro studies demonstrated that, at the recommended dosage, edaravone and its metabolites are not expected to significantly inhibit CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A), conjugating enzymes UGT1A1 and UGT2B7, or other transporters (P-gp, OATP1B1, OATP1B3, OAT1, OCT2, MATE1, and MATE2-K) in humans. Edaravone and its metabolites are not expected to induce CYP1A2, or CYP2B6, at the recommended dosage of edaravone. In vitro data indicated that edaravone was not a substrate of OATP1B1 or OATP1B3."],"indications_and_usage":["1 INDICATIONS AND USAGE RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions: Advise patients to seek immediate medical care ( 5.1 ) • Sulfite Allergic Reactions: RADICAVA and RADICAVA ORS contain sodium bisulfite, which may cause allergic type reactions, including anaphylactic symptoms and asthmatic episodes in susceptible people ( 5.2 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported in spontaneous postmarketing reports with RADICAVA. Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA and/or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves [see Contraindications (4) ]. 5.2 Sulfite Allergic Reactions RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity occurs more frequently in asthmatic than non-asthmatic people."],"clinical_studies_table":["
TreatmentChange from BaselineLS Mean ± SE (95% CI)Treatment Difference (RADICAVA – placebo [95% CI])p-value
RADICAVA IV−5.01±0.642.49 (0.99, 3.98)0.0013
Placebo−7.50±0.66
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a 26-week carcinogenicity study in male and female transgenic (Tg rasH2) mice, oral administration of edaravone (0 [water control], 0 [vehicle control], 100, 150, or 350 mg/kg) resulted in no increase in tumors. In a 2-year carcinogenicity study in rats, oral administration of edaravone (0, 50, 100, or 200 mg/kg in males; 0, 50, 100, or 250 mg/kg in females) resulted in no increase in tumors. Carcinogenicity studies of edaravone using the intravenous route have not been conducted. Mutagenesis Edaravone was negative in in vitro (bacterial reverse mutation and Chinese hamster lung chromosomal aberration) and in vivo (mouse micronucleus) assays. Impairment of Fertility Intravenous administration of edaravone (0, 3, 20, or 200 mg/kg) prior to and throughout mating in male and female rats and continuing in females to gestation day 7 had no effect on fertility; however, disruption of the estrus cycle and mating behavior was observed at the highest dose tested. No effects on reproductive function were observed at the lower doses, which are up to approximately 3 times the RHD for RADICAVA (60 mg) on a body surface area (mg/m 2 ) basis. Fertility studies of edaravone using the oral route have not been conducted. 13.2 Animal Toxicology and/or Pharmacology Oral administration of edaravone (0, 10, 30, 100, or 300 mg/kg/day) in dogs for 39 weeks resulted in neurotoxicity, characterized by white matter vacuolation in the spinal cord and vacuolation and nerve fiber atrophy in the sciatic nerve, at the two highest doses tested. The microscopic findings were accompanied by gait abnormalities, loss of patellar reflex, and inability to rise. Plasma edaravone exposures (C max and AUC) at the higher no-effect dose for neurotoxicity (30 mg/kg/day) were approximately 2 times those in humans at the recommended human dose of RADICAVA ORS (105 mg)."],"adverse_reactions_table":["
Adverse ReactionRADICAVA IV(N=184)%Placebo(N=184)%
Contusion159
Gait disturbance139
Headache106
Dermatitis85
Eczema74
Respiratory failure, respiratory disorder, hypoxia64
Glycosuria42
Tinea infection42
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Hypersensitivity Reactions Advise patients to seek immediate medical care if they experience signs or symptoms of a hypersensitivity reaction [see Warnings and Precautions (5.1) ]. Sulfite Allergic Reactions Advise patients about potential for sulfite sensitivity. Inform patients that RADICAVA and RADICAVA ORS contain sodium bisulfite, which may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, and to seek immediate medical care if they experience these signs or symptoms [see Warnings and Precautions (5.2) ]. Pregnancy and Breastfeeding Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during RADICAVA or RADICAVA ORS therapy [see Use in Specific Populations (8.1) ] . Advise patients to notify their healthcare provider if they intend to breastfeed or are breastfeeding an infant [see Use in Specific Populations (8.2) ] . RADICAVA ORS Administration Advise patients to take RADICAVA ORS in the morning on an empty stomach. Instruct patients to fast 8 hours before each dose if they consume a high-fat meal, 4 hours before each dose if they consume a low-fat meal, or 2 hours before each dose if they consume a caloric supplement [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . Also instruct patients to not to consume food for 1 hour after each dose. Advise caregivers, if administering RADICAVA ORS via feeding tube, to use a catheter-tip syringe and flush the feeding tube with approximately 1 ounce (30 mL) of water before and after use (see Instructions for Use ) . Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 RADICAVA and RADICAVA ORS are registered trademarks of K.K. BCJ-94. © 2025 Tanabe Pharma America, Inc. All rights reserved. 22022-3 Iss. 12/2025 Information for Patients PATIENT INFORMATION RADICAVA (ra di ká vah) (edaravone injection) for intravenous infusion RADICAVA ORS (ra di ká vah o r s) (edaravone oral suspension) administered by mouth or via feeding tube What are RADICAVA ® and RADICAVA ORS ® ? RADICAVA and RADICAVA ORS are prescription medicines used to treat people with amyotrophic lateral sclerosis (ALS). It is not known if RADICAVA or RADICAVA ORS are safe and effective in children. Do not receive RADICAVA or RADICAVA ORS if you are allergic to edaravone or any of the ingredients in RADICAVA and RADICAVA ORS. See the end of this leaflet for a complete list of ingredients in RADICAVA and RADICAVA ORS. Before you take RADICAVA or RADICAVA ORS, tell your healthcare provider about all of your medical conditions, including if you: • have asthma. • are allergic to other medicines. • are pregnant or plan to become pregnant. It is not known if RADICAVA or RADICAVA ORS will harm your unborn baby. • are breastfeeding or plan to breastfeed. It is not known if RADICAVA or RADICAVA ORS passes into your breastmilk. You and your healthcare provider should decide if you will receive RADICAVA or RADICAVA ORS or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive RADICAVA? • You will be prescribed RADICAVA by a healthcare provider and told how often you will receive RADICAVA. • RADICAVA will be given by intravenous (IV) infusion into your vein. • It takes about 1 hour to receive the full dose of RADICAVA. • Your healthcare provider will monitor you closely during your treatment with RADICAVA. How will I take RADICAVA ORS? • See the detailed Instructions for Use on how to take RADICAVA ORS at the end of this Patient Information leaflet. • You will be prescribed RADICAVA ORS by a healthcare provider and told how often you will take RADICAVA ORS. • RADICAVA ORS is to be taken by mouth or by using a feeding tube. • RADICAVA ORS should be taken in the morning on an empty stomach. You should stop eating at bedtime. • Do not eat or drink anything 8 hours before each dose of RADICAVA ORS if you eat a high-fat meal. • Do not eat or drink anything 4 hours before each dose of RADICAVA ORS if you eat a low-fat meal. • Do not eat or drink anything 2 hours before each dose of RADICAVA ORS if you take a calorie supplement. • You should wait at least 1 hour after taking your medicine before eating or drinking anything except water. What are the possible side effects of RADICAVA and RADICAVA ORS? RADICAVA and RADICAVA ORS may cause serious side effects including: 1. Hypersensitivity (allergic) reactions. Hypersensitivity reactions have happened in people receiving RADICAVA or taking RADICAVA ORS and can happen after your medicine has been given. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: 2. Sulfite allergic reactions. RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe allergic reactions, for example, asthma episodes, in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects and allergic reactions. The most common side effects of RADICAVA and RADICAVA ORS include bruising (contusion), problems walking (gait disturbance), and headache. These are not all the possible side effects of RADICAVA and RADICAVA ORS. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch or Tanabe Pharma America, Inc. at 1-888-292-0058. What are the ingredients in RADICAVA and RADICAVA ORS? Active ingredient: edaravone RADICAVA Inactive ingredients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride, phosphoric acid, and sodium hydroxide. RADICAVA ORS Inactive ingredients: L-cysteine hydrochloride hydrate, polyvinyl alcohol, simethicone emulsion, sodium bisulfite, sorbitol, and xanthan gum. Phosphoric acid and sodium hydroxide are added to adjust to pH 4. Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 For more information, go to www.Radicava.com or call 1-888-292-0058. RADICAVA and RADICAVA ORS are registered trademarks of K.K. BCJ-94. © 2025 Tanabe Pharma America, Inc. All rights reserved. This Patient Information has been approved by the U.S. Food and Drug Administration 22022-3 Issued: 12/2025 Instructions for Use INSTRUCTIONS FOR USE RADICAVA (ra di ká vah) ORS (edaravone) oral suspension Read this Instructions for Use before you take RADICAVA ORS ® for the first time and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Important information about measuring RADICAVA ORS: Always measure your prescribed dose of RADICAVA ORS using the oral syringe provided. Ask your healthcare provider or pharmacist who provided the medicine any questions you have about how to measure your prescribed dose. If you miss a dose, do not take 2 doses of RADICAVA ORS the next day. Do not take a dose of RADICAVA ORS on days 15 through 28. How to prepare RADICAVA ORS : Keep this Instructions for Use handy when preparing the treatment. • If your healthcare provider prescribes a Starter Kit, you will receive 2 bottles of RADICAVA ORS. Each bottle will contain 35 mL of RADICAVA ORS for a total of 70 mL to be used for your first treatment cycle of 14 days. Only open the second bottle when you have finished the first bottle. • If you were not prescribed the Starter Kit, for each treatment cycle you will receive 1 bottle of RADICAVA ORS that contains a total of 50 mL of RADICAVA ORS. After the first treatment cycle, RADICAVA ORS is to be used for 10 days out of 14 day periods. • Only use the bottle adapter and the 2 reusable 5 mL oral syringes provided with the bottle. Do not use a household teaspoon to measure your medicine. How to store RADICAVA ORS: • Store RADICAVA ORS upright at room temperature between 68°F to 77°F (20°C to 25°C). Protect from light. • Opening the bottle: • When you open the bottle of RADICAVA ORS for the first use, write the date you open the bottle on the bottle label. • After opening the bottle of RADICAVA ORS, use within 15 days. • After a bottle of RADICAVA ORS has been opened and used, a white crust may form on the neck or on the side of the bottle. This is due to normal use and RADICAVA ORS can continue to be uses as prescribed. • Keep bottle tightly closed between each use. • Throw away (discard) any RADICAVA ORS that is not used within 15 days after opening the bottle or within 30 days from the date of shipment shown on the carton pharmacy label, whichever happens first. Ask your pharmacist how to properly throw away (discard) RADICAVA ORS you are no longer able to use. • Keep RADICAVA ORS and all medicines out of the reach of children. Each RADICAVA ORS carton contains: • 1 RADICAVA ORS bottle • 1 bottle adapter • 2 (5 mL) reusable oral syringes Use a new 5 mL oral syringe and bottle adapter when using a new bottle of RADICAVA ORS (see Figure A) Figure A Important information: • Keep these instructions for future use. • Do not share RADICAVA ORS with anyone else. • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. • People who have problems using their hands may need assistance to draw up and give the correct dose of RADICAVA ORS. How to take RADICAVA ORS: Take RADICAVA ORS as prescribed by your healthcare provider. Dosing Information: RADICAVA ORS has 2 different dosing schedules: • For the first treatment cycle, you will take RADICAVA ORS every day for 14 days, followed by 14 days without the medicine. • For the cycles after the first treatment cycle, you will take RADICAVA ORS daily for 10 out of 14 days, followed by 14 days without the medicine. How RADICAVA ORS will be provided: • If your healthcare provider prescribes the Starter Kit, you will receive 2 bottles of RADICAVA ORS. Each bottle contains 35 mL of RADICAVA ORS for a total of 70 mL to deliver 14 doses. o There may be some medicine that remains in each bottle after the dose on day 7 and day 14 of the first treatment cycle. Throw away (discard) any medicine that remains. • If you were not prescribed the starter kit, for each treatment cycle, you will receive 1 bottle of RADICAVA ORS that contains a total of 50 mL of RADICAVA ORS to deliver 10 doses. o There may be some medicine that remains in each bottle after 10 doses. Throw away (discard) any medicine that remains. Fasting Information: • Do not eat or drink anything 8 hours before each dose of RADICAVA ORS if you eat a high-fat meal. • Do not eat or drink anything 4 hours before each dose of RADICAVA ORS if you eat a low-fat meal. • Do not eat or drink anything 2 hours before each dose of RADICAVA ORS if you take a calorie supplement. • You should wait at least 1 hour after taking your medicine before eating or drinking anything except water. Step 1: Before each use of RADICAVA ORS: Before opening the bottle, turn it upside down (invert) and shake vigorously up and down for at least 30 seconds (see Figure B). Look at the liquid medicine to make sure it is mixed well. If you see any small pieces at the bottom of the bottle, invert the bottle and shake it up and down for another 30 seconds or until you can no longer see the pieces at the bottom of the bottle (see Figure B). If the liquid medicine all looks the same, you can proceed to Step 2. Shake up and down for at least 30 seconds Figure B Step 2: Open the bottle by firmly pressing down on the bottle cap and turning it counterclockwise (to the left). Place the open bottle upright on a flat surface. Do not throw away the bottle cap; you will need to replace it after taking each dose. First time use of a bottle only. This must only be done 1 time for each bottle. Insert the ribbed end of the bottle adapter into the bottle by firmly pressing it in as far as it will go (see Figure C). Do not remove the bottle adapter. Figure C Step 3: Remove the oral syringe from plastic wrap and make sure the plunger is inserted all the way into the barrel. Push the oral syringe plunger toward its tip to remove excess air (see Figure D). Insert the oral syringe into the opening of the bottle adapter until it is firmly in place (see Figure E). Turn the bottle upside down and slowly pull the plunger to remove a small amount of liquid (see Figure F). Figure D Figure E Figure F Step 4: Keep the bottle upside down and pull the plunger until it goes up to the last line (5 mL) (see Figure G). While keeping the plunger in the same position, turn the bottle upright, and place it carefully on a flat surface. Remove the oral syringe by gently twisting or pulling it out from the bottle (see Figure H). Check the amount of medicine again before moving on to the next step (see Figure I). Note: Do not remove the oral syringe while the bottle is upside down (medicine may leak out through the adapter). Note: If the dose is not correct, insert the oral syringe tip firmly into the bottle adapter. Push the plunger all the way in so that the medicine flows back into the bottle. Turn the bottle upside down. Repeat Step 4. Figure G Figure H Figure I Step 5: Place the tip of the oral syringe in the mouth and aim towards the inside of the cheek. Slowly press down on the plunger until the oral syringe is empty. Swallow all of the medicine (see Figure J). If needed, you can use up to 8 ounces or 1 cup of water to help swallow the medicine. Note: It is normal for a small amount of medicine to remain in the tip of the syringe after taking. Figure J Step 6: Leave the bottle adapter inside the bottle. Place the bottle cap on the bottle and turn the cap clockwise (to the right). Keep bottle tightly closed between each use (see Figure K). Figure K Step 7: Remove the plunger from the oral syringe barrel by pulling the plunger and the barrel away from each other. Rinse the oral syringe (plunger and barrel) with water only . Allow it to air dry. Figure L Step 8: When the oral syringe (plunger and barrel) is dry, put the plunger back into the oral syringe barrel. Do not throw away the oral syringe . Store the syringe in a clean, dry place. You must complete Steps 1 through 4 under \"How to take RADICAVA ORS\" before starting Step 9 under \"How to take a dose of RADICAVA ORS oral suspension through a feeding tube.\" How to take a dose of RADICAVA ORS oral suspension through a feeding tube: Step 9: Using a catheter-tip syringe, flush the feeding tube with 1 ounce (30 mL) of water (see Figure M). Figure M Step 10: Place the oral syringe provided (containing the 5 mL of RADICAVA ORS) into the feeding tube. Slowly push down the plunger until the oral syringe is empty (see Figure N). Figure N Step 11: Using a catheter-tip syringe, flush the feeding tube with 1 ounce (30 mL) of water after taking dose of RADICAVA ORS (see Figure O). Figure O Step 12: Leave the adapter in the bottle. Place the bottle cap on the bottle and turn it clockwise (to the right) to close the bottle. Keep the bottle tightly closed between each use (see Figure P). Figure P Step 13: Remove the plunger from the oral syringe barrel by pulling the plunger and barrel away from each other. Rinse the oral syringe (plunger and barrel) with water only (see Figure Q). Allow it to air dry. Figure Q Step 14: When the oral syringe (plunger and barrel) are dry, put the plunger back into the oral syringe barrel. Do not throw away the oral syringe. Store the oral syringe in a clean, dry place. Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 For more information, go to www.Radicava.com or call 1- 888-292-0058. RADICAVA ORS ® is a registered trademarks of K.K. BCJ-94. © 2025 Tanabe Pharma America, Inc. All rights reserved. This Instructions for Use has been approved by the U.S. Food and Drug Administration. 22022-3 Issued: 12/2025 ifu-figure-a ifu-figure-b ifu-figure-c ifu-figure-d ifu-figure-e ifu-figure-f ifu-figure-g ife-figure-h ifu-figure-i ifu-figure-j ifg-figure-k ifu-figure-l ifu-figure-m ifu-figure-n ifu-figure-o ifu-figure-p ifu-figure-q","Information for Patients PATIENT INFORMATION RADICAVA (ra di ká vah) (edaravone injection) for intravenous infusion RADICAVA ORS (ra di ká vah o r s) (edaravone oral suspension) administered by mouth or via feeding tube What are RADICAVA ® and RADICAVA ORS ® ? RADICAVA and RADICAVA ORS are prescription medicines used to treat people with amyotrophic lateral sclerosis (ALS). It is not known if RADICAVA or RADICAVA ORS are safe and effective in children. Do not receive RADICAVA or RADICAVA ORS if you are allergic to edaravone or any of the ingredients in RADICAVA and RADICAVA ORS. See the end of this leaflet for a complete list of ingredients in RADICAVA and RADICAVA ORS. Before you take RADICAVA or RADICAVA ORS, tell your healthcare provider about all of your medical conditions, including if you: • have asthma. • are allergic to other medicines. • are pregnant or plan to become pregnant. It is not known if RADICAVA or RADICAVA ORS will harm your unborn baby. • are breastfeeding or plan to breastfeed. It is not known if RADICAVA or RADICAVA ORS passes into your breastmilk. You and your healthcare provider should decide if you will receive RADICAVA or RADICAVA ORS or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive RADICAVA? • You will be prescribed RADICAVA by a healthcare provider and told how often you will receive RADICAVA. • RADICAVA will be given by intravenous (IV) infusion into your vein. • It takes about 1 hour to receive the full dose of RADICAVA. • Your healthcare provider will monitor you closely during your treatment with RADICAVA. How will I take RADICAVA ORS? • See the detailed Instructions for Use on how to take RADICAVA ORS at the end of this Patient Information leaflet. • You will be prescribed RADICAVA ORS by a healthcare provider and told how often you will take RADICAVA ORS. • RADICAVA ORS is to be taken by mouth or by using a feeding tube. • RADICAVA ORS should be taken in the morning on an empty stomach. You should stop eating at bedtime. • Do not eat or drink anything 8 hours before each dose of RADICAVA ORS if you eat a high-fat meal. • Do not eat or drink anything 4 hours before each dose of RADICAVA ORS if you eat a low-fat meal. • Do not eat or drink anything 2 hours before each dose of RADICAVA ORS if you take a calorie supplement. • You should wait at least 1 hour after taking your medicine before eating or drinking anything except water. What are the possible side effects of RADICAVA and RADICAVA ORS? RADICAVA and RADICAVA ORS may cause serious side effects including: 1. Hypersensitivity (allergic) reactions. Hypersensitivity reactions have happened in people receiving RADICAVA or taking RADICAVA ORS and can happen after your medicine has been given. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: 2. Sulfite allergic reactions. RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe allergic reactions, for example, asthma episodes, in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects and allergic reactions. The most common side effects of RADICAVA and RADICAVA ORS include bruising (contusion), problems walking (gait disturbance), and headache. These are not all the possible side effects of RADICAVA and RADICAVA ORS. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to www.fda.gov/medwatch or Tanabe Pharma America, Inc. at 1-888-292-0058. What are the ingredients in RADICAVA and RADICAVA ORS? Active ingredient: edaravone RADICAVA Inactive ingredients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride, phosphoric acid, and sodium hydroxide. RADICAVA ORS Inactive ingredients: L-cysteine hydrochloride hydrate, polyvinyl alcohol, simethicone emulsion, sodium bisulfite, sorbitol, and xanthan gum. Phosphoric acid and sodium hydroxide are added to adjust to pH 4. Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 For more information, go to www.Radicava.com or call 1-888-292-0058. RADICAVA and RADICAVA ORS are registered trademarks of K.K. BCJ-94. © 2025 Tanabe Pharma America, Inc. All rights reserved. This Patient Information has been approved by the U.S. Food and Drug Administration 22022-3 Issued: 12/2025"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • RADICAVA: The recommended dosage is 60 mg administered as an intravenous infusion over 60 minutes ( 2.1 ) • RADICAVA ORS: The recommended dosage is 105 mg (5 mL) taken orally or via feeding tube in the morning after overnight fasting. Food should not be consumed for 1 hour after administration except water ( 2.1 , 2.3 ) • For RADICAVA and RADICAVA ORS: • Initial treatment cycle: daily dosing for 14 days followed by a 14- day drug-free period ( 2.1 ) • Subsequent treatment cycles: daily dosing for 10 days out of 14- day periods, followed by 14-day drug-free periods ( 2.1 ) 2.1 Dosage Information The recommended dosage of RADICAVA and RADICAVA ORS is as follows: • RADICAVA: an intravenous infusion of 60 mg administered over a 60-minute period • RADICAVA ORS: 105 mg (5 mL) taken orally or via feeding tube in the morning after overnight fasting [ see Dosage and Administration (2.3) ] Administer RADICAVA or RADICAVA ORS according to the following schedule: • An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period • Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods 2.2 Preparation and Administration Information for RADICAVA Injection RADICAVA is for intravenous infusion only. Preparation Do not use if the oxygen indicator has turned blue or purple before opening the package . Once the overwrap package is opened, use within 24 hours [see How Supplied/Storage and Handling (16.1 , 16.2) ]. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Administration Administer each 60 mg dose of RADICAVA injection as two consecutive 30 mg intravenous infusion bags over a total of 60 minutes (infusion rate approximately 1 mg per minute [3.33 mL per minute]). Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction [see Warnings and Precautions (5.1 , 5.2) ] . Other medications should not be injected into the infusion bag or mixed with RADICAVA. 2.3 Preparation and Administration Information for RADICAVA ORS Oral Suspension See the Instruction for Use for further preparation and administration details. Preparation Prior to opening the bottle, turn it upside down (invert) and shake vigorously up and down for at least 30 seconds. Administration RADICAVA ORS can be administered by mouth or via feeding tube (see Feeding Tube Administration ) . RADICAVA ORS should be taken in the morning on an empty stomach after overnight fasting. Food should not be consumed for 1 hour after administration except water [see Clinical Pharmacology (12.3) ] . See Table 1 for specific fasting conditions. Table 1: RADICAVA ORS Administration Relative to Type of Food Consumption Type of food/caloric supplement consumed Fasting time before and after RADICAVA ORS dose administration with regards to meal type High-fat meal (800-1,000 calories, 50% fat) 8 hours before administration and one hour after administration Low-fat meal (400-500 calories, 25% fat) 4 hours before administration and one hour after administration Caloric supplement (250 calories, e.g., protein drink) 2 hours before administration and one hour after administration Administer RADICAVA ORS using a 5 mL oral syringe that comes with the product. A household teaspoon is not an adequate measuring device. Dispose of any RADICAVA ORS that is not used within 15 days after opening the bottle or within the 30 days from the date of shipment indicated on the carton pharmacy label, which ever happens first. Feeding Tube Administration • Nasogastric (NG) tubes or percutaneous endoscopic gastrostomy (PEG) tubes made of silicone, polyvinyl chloride (PVC), or polyurethane can be used • Before and after administration, use a catheter-tip syringe to flush the tube with at least 1 ounce (30 mL) of water 2.4 Switching from RADICAVA to RADICAVA ORS Patients treated with 60 mg of RADICAVA intravenous infusion may be switched to 105 mg (5 mL) RADICAVA ORS using the same dosing frequency. Upon switching to RADICAVA ORS, patients should follow RADICAVA ORS dosing recommendations with regards to food consumption [see Dosage and Administration (2.3) ] .","2.1 Dosage Information The recommended dosage of RADICAVA and RADICAVA ORS is as follows: • RADICAVA: an intravenous infusion of 60 mg administered over a 60-minute period • RADICAVA ORS: 105 mg (5 mL) taken orally or via feeding tube in the morning after overnight fasting [ see Dosage and Administration (2.3) ] Administer RADICAVA or RADICAVA ORS according to the following schedule: • An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period • Subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods","2.2 Preparation and Administration Information for RADICAVA Injection RADICAVA is for intravenous infusion only. Preparation Do not use if the oxygen indicator has turned blue or purple before opening the package . Once the overwrap package is opened, use within 24 hours [see How Supplied/Storage and Handling (16.1 , 16.2) ]. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Administration Administer each 60 mg dose of RADICAVA injection as two consecutive 30 mg intravenous infusion bags over a total of 60 minutes (infusion rate approximately 1 mg per minute [3.33 mL per minute]). Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction [see Warnings and Precautions (5.1 , 5.2) ] . Other medications should not be injected into the infusion bag or mixed with RADICAVA.","2.3 Preparation and Administration Information for RADICAVA ORS Oral Suspension See the Instruction for Use for further preparation and administration details. Preparation Prior to opening the bottle, turn it upside down (invert) and shake vigorously up and down for at least 30 seconds. Administration RADICAVA ORS can be administered by mouth or via feeding tube (see Feeding Tube Administration ) . RADICAVA ORS should be taken in the morning on an empty stomach after overnight fasting. Food should not be consumed for 1 hour after administration except water [see Clinical Pharmacology (12.3) ] . See Table 1 for specific fasting conditions. Table 1: RADICAVA ORS Administration Relative to Type of Food Consumption Type of food/caloric supplement consumed Fasting time before and after RADICAVA ORS dose administration with regards to meal type High-fat meal (800-1,000 calories, 50% fat) 8 hours before administration and one hour after administration Low-fat meal (400-500 calories, 25% fat) 4 hours before administration and one hour after administration Caloric supplement (250 calories, e.g., protein drink) 2 hours before administration and one hour after administration Administer RADICAVA ORS using a 5 mL oral syringe that comes with the product. A household teaspoon is not an adequate measuring device. Dispose of any RADICAVA ORS that is not used within 15 days after opening the bottle or within the 30 days from the date of shipment indicated on the carton pharmacy label, which ever happens first. Feeding Tube Administration • Nasogastric (NG) tubes or percutaneous endoscopic gastrostomy (PEG) tubes made of silicone, polyvinyl chloride (PVC), or polyurethane can be used • Before and after administration, use a catheter-tip syringe to flush the tube with at least 1 ounce (30 mL) of water"],"spl_product_data_elements":["RADICAVA EDARAVONE EDARAVONE EDARAVONE SODIUM BISULFITE CYSTEINE HYDROCHLORIDE SODIUM CHLORIDE SODIUM HYDROXIDE PHOSPHORIC ACID WATER RADICAVA ORS EDARAVONE RADICAVA ORS EDARAVONE EDARAVONE EDARAVONE POLYVINYL ALCOHOL, UNSPECIFIED SODIUM BISULFITE CYSTEINE HYDROCHLORIDE SODIUM HYDROXIDE PHOSPHORIC ACID SORBITOL DIMETHICONE, UNSPECIFIED WATER RADICAVA ORS EDARAVONE RADICAVA ORS EDARAVONE EDARAVONE EDARAVONE POLYVINYL ALCOHOL, UNSPECIFIED XANTHAN GUM SODIUM BISULFITE CYSTEINE HYDROCHLORIDE SODIUM HYDROXIDE PHOSPHORIC ACID SORBITOL DIMETHICONE, UNSPECIFIED WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS RADICAVA is supplied for intravenous infusion in a single-dose polypropylene bag containing 30 mg of edaravone in 100 mL of clear, colorless aqueous solution. RADICAVA ORS is supplied as an oral suspension in a multi-dose amber glass bottle 105 mg/5 mL of white to off-white color. • Injection: 30 mg/100 mL in a single-dose polypropylene bag ( 3 ) • Oral suspension: 105 mg/5 mL in a multi-dose amber glass bottle ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, may cause fetal harm. ( 8.1 ) 8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of RADICAVA or RADICAVA ORS in pregnant women. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. Most of these effects occurred at doses that were also associated with maternal toxicity (see Animal Data ) . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk for major birth defects and miscarriage in patients with ALS is unknown. Data Animal Data In rats, intravenous administration of edaravone (0, 3, 30, or 300 mg/kg/day) throughout the period of organogenesis resulted in reduced fetal weight at all doses. In dams allowed to deliver naturally, offspring weight was reduced at the highest dose tested. Maternal toxicity was also observed at the highest dose tested. There were no adverse effects on reproductive function in the offspring. A no-effect dose for embryofetal developmental toxicity was not identified; the low dose is less than the recommended human dose of 60 mg for RADICAVA on a body surface area (mg/m 2 ) basis. In rabbits, intravenous administration of edaravone (0, 3, 20, or 100 mg/kg/day) throughout the period of organogenesis resulted in embryofetal death at the highest dose tested, which was associated with maternal toxicity. The higher no-effect dose for embryofetal developmental toxicity is approximately 6 times the recommended human dose (RHD) for RADICAVA on a body surface area (mg/m 2 ) basis. The effects on offspring of edaravone (0, 3, 20, or 200 mg/kg/day), administered by intravenous injection to rats from GD 17 throughout lactation, were assessed in two studies. In the first study, offspring mortality was observed at the high dose and increased activity was observed at the mid and high doses. In the second study, there was an increase in stillbirths, offspring mortality, and delayed physical development (vaginal opening) at the highest dose tested. Reproduction function in offspring was not affected in either study. Maternal toxicity was evident in both studies at all but the lowest dose tested. The no-effect dose for developmental toxicity (3 mg/kg/day) is less than the RHD on a mg/m 2 basis. Reproductive and developmental toxicology studies of edaravone using the oral route have not been conducted. 8.2 Lactation Risk Summary There are no data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Edaravone and its metabolites are excreted in the milk of lactating rats. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RADICAVA and RADICAVA ORS and any potential adverse effects on the breastfed infant from RADICAVA and RADICAVA ORS or from the underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness of RADICAVA or RADICAVA ORS in pediatric patients have not been established 8.5 Geriatric Use Of the 184 patients with ALS who received RADICAVA in 3 placebo-controlled clinical trials, a total of 53 patients were 65 years of age and older, including 2 patients 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"information_for_patients_table":["have asthma.are allergic to other medicines.are pregnant or plan to become pregnant. It is not known if RADICAVA or RADICAVA ORS will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if RADICAVA or RADICAVA ORS passes into your breastmilk.You and your healthcare provider should decide if you will receive RADICAVA or RADICAVA ORS or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.You will be prescribed RADICAVA by a healthcare provider and told how often you will receive RADICAVA.RADICAVA will be given by intravenous (IV) infusion into your vein.It takes about 1 hour to receive the full dose of RADICAVA.Your healthcare provider will monitor you closely during your treatment with RADICAVA.How will I take RADICAVA ORS?See the detailed Instructions for Use on how to take RADICAVA ORS at the end of this Patient Information leaflet.You will be prescribed RADICAVA ORS by a healthcare provider and told how often you will take RADICAVA ORS.RADICAVA ORS is to be taken by mouth or by using a feeding tube.RADICAVA ORS should be taken in the morning on an empty stomach. You should stop eating at bedtime. Do not eat or drink anything 8 hours before each dose of RADICAVA ORS if you eat a high-fat meal. Do not eat or drink anything 4 hours before each dose of RADICAVA ORS if you eat a low-fat meal.Do not eat or drink anything 2 hours before each dose of RADICAVA ORS if you take a calorie supplement.You should wait at least 1 hour after taking your medicine before eating or drinking anything except water.
PATIENT INFORMATION RADICAVA (ra di ká vah)(edaravone injection) for intravenous infusionRADICAVA ORS (ra di ká vah o r s)(edaravone oral suspension)administered by mouth or via feeding tube
What are RADICAVA® and RADICAVA ORS®?RADICAVA and RADICAVA ORS are prescription medicines used to treat people with amyotrophic lateral sclerosis (ALS).It is not known if RADICAVA or RADICAVA ORS are safe and effective in children.
Do not receive RADICAVA or RADICAVA ORS if you are allergic to edaravone or any of the ingredients in RADICAVA and RADICAVA ORS. See the end of this leaflet for a complete list of ingredients in RADICAVA and RADICAVA ORS.
Before you take RADICAVA or RADICAVA ORS, tell your healthcare provider about all of your medical conditions, including if you:
••••
How will I receive RADICAVA?
••••••••••••
What are the possible side effects of RADICAVA and RADICAVA ORS?RADICAVA and RADICAVA ORS may cause serious side effects including:1. Hypersensitivity (allergic) reactions. Hypersensitivity reactions have happened in people receiving RADICAVA or taking RADICAVA ORS and can happen after your medicine has been given. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:2. Sulfite allergic reactions. RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe allergic reactions, for example, asthma episodes, in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects and allergic reactions.The most common side effects of RADICAVA and RADICAVA ORS include bruising (contusion), problems walking (gait disturbance), and headache.These are not all the possible side effects of RADICAVA and RADICAVA ORS. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects.You may report side effects to FDA at 1-800-FDA-1088.You may also report side effects to www.fda.gov/medwatch or Tanabe Pharma America, Inc. at 1-888-292-0058.
What are the ingredients in RADICAVA and RADICAVA ORS?Active ingredient: edaravoneRADICAVA Inactive ingredients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride, phosphoric acid, and sodium hydroxide.RADICAVA ORS Inactive ingredients: L-cysteine hydrochloride hydrate, polyvinyl alcohol, simethicone emulsion, sodium bisulfite, sorbitol, and xanthan gum. Phosphoric acid and sodium hydroxide are added to adjust to pH 4.Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 For more information, go to www.Radicava.com or call 1-888-292-0058.RADICAVA and RADICAVA ORS are registered trademarks of K.K. BCJ-94.© 2025 Tanabe Pharma America, Inc. All rights reserved.
","have asthma.are allergic to other medicines.are pregnant or plan to become pregnant. It is not known if RADICAVA or RADICAVA ORS will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if RADICAVA or RADICAVA ORS passes into your breastmilk.You and your healthcare provider should decide if you will receive RADICAVA or RADICAVA ORS or breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.You will be prescribed RADICAVA by a healthcare provider and told how often you will receive RADICAVA.RADICAVA will be given by intravenous (IV) infusion into your vein.It takes about 1 hour to receive the full dose of RADICAVA.Your healthcare provider will monitor you closely during your treatment with RADICAVA.How will I take RADICAVA ORS?See the detailed Instructions for Use on how to take RADICAVA ORS at the end of this Patient Information leaflet.You will be prescribed RADICAVA ORS by a healthcare provider and told how often you will take RADICAVA ORS.RADICAVA ORS is to be taken by mouth or by using a feeding tube.RADICAVA ORS should be taken in the morning on an empty stomach. You should stop eating at bedtime. Do not eat or drink anything 8 hours before each dose of RADICAVA ORS if you eat a high-fat meal. Do not eat or drink anything 4 hours before each dose of RADICAVA ORS if you eat a low-fat meal.Do not eat or drink anything 2 hours before each dose of RADICAVA ORS if you take a calorie supplement.You should wait at least 1 hour after taking your medicine before eating or drinking anything except water.
PATIENT INFORMATION RADICAVA (ra di ká vah)(edaravone injection) for intravenous infusionRADICAVA ORS (ra di ká vah o r s)(edaravone oral suspension)administered by mouth or via feeding tube
What are RADICAVA® and RADICAVA ORS®?RADICAVA and RADICAVA ORS are prescription medicines used to treat people with amyotrophic lateral sclerosis (ALS).It is not known if RADICAVA or RADICAVA ORS are safe and effective in children.
Do not receive RADICAVA or RADICAVA ORS if you are allergic to edaravone or any of the ingredients in RADICAVA and RADICAVA ORS. See the end of this leaflet for a complete list of ingredients in RADICAVA and RADICAVA ORS.
Before you take RADICAVA or RADICAVA ORS, tell your healthcare provider about all of your medical conditions, including if you:
••••
How will I receive RADICAVA?
••••••••••••
What are the possible side effects of RADICAVA and RADICAVA ORS?RADICAVA and RADICAVA ORS may cause serious side effects including:1. Hypersensitivity (allergic) reactions. Hypersensitivity reactions have happened in people receiving RADICAVA or taking RADICAVA ORS and can happen after your medicine has been given. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:2. Sulfite allergic reactions. RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe allergic reactions, for example, asthma episodes, in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma. Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms:Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects and allergic reactions.The most common side effects of RADICAVA and RADICAVA ORS include bruising (contusion), problems walking (gait disturbance), and headache.These are not all the possible side effects of RADICAVA and RADICAVA ORS. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects.You may report side effects to FDA at 1-800-FDA-1088.You may also report side effects to www.fda.gov/medwatch or Tanabe Pharma America, Inc. at 1-888-292-0058.
What are the ingredients in RADICAVA and RADICAVA ORS?Active ingredient: edaravoneRADICAVA Inactive ingredients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride, phosphoric acid, and sodium hydroxide.RADICAVA ORS Inactive ingredients: L-cysteine hydrochloride hydrate, polyvinyl alcohol, simethicone emulsion, sodium bisulfite, sorbitol, and xanthan gum. Phosphoric acid and sodium hydroxide are added to adjust to pH 4.Marketed and distributed by: Tanabe Pharma America, Inc. Jersey City, NJ 07310 For more information, go to www.Radicava.com or call 1-888-292-0058.RADICAVA and RADICAVA ORS are registered trademarks of K.K. BCJ-94.© 2025 Tanabe Pharma America, Inc. All rights reserved.
"],"dosage_and_administration_table":["
Table 1: RADICAVA ORS Administration Relative to Type of Food Consumption
Type of food/caloric supplement consumedFasting time before and after RADICAVA ORS dose administration with regards to meal type
High-fat meal (800-1,000 calories, 50% fat)8 hours before administration and one hour after administration
Low-fat meal (400-500 calories, 25% fat)4 hours before administration and one hour after administration
Caloric supplement (250 calories, e.g., protein drink)2 hours before administration and one hour after administration
","
Table 1: RADICAVA ORS Administration Relative to Type of Food Consumption
Type of food/caloric supplement consumedFasting time before and after RADICAVA ORS dose administration with regards to meal type
High-fat meal (800-1,000 calories, 50% fat)8 hours before administration and one hour after administration
Low-fat meal (400-500 calories, 25% fat)4 hours before administration and one hour after administration
Caloric supplement (250 calories, e.g., protein drink)2 hours before administration and one hour after administration
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Oral administration of edaravone (0, 10, 30, 100, or 300 mg/kg/day) in dogs for 39 weeks resulted in neurotoxicity, characterized by white matter vacuolation in the spinal cord and vacuolation and nerve fiber atrophy in the sciatic nerve, at the two highest doses tested. The microscopic findings were accompanied by gait abnormalities, loss of patellar reflex, and inability to rise. Plasma edaravone exposures (C max and AUC) at the higher no-effect dose for neurotoxicity (30 mg/kg/day) were approximately 2 times those in humans at the recommended human dose of RADICAVA ORS (105 mg)."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-soft-bag","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-carton","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-ors-starter-label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-ors-starter-inner-carton","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-ors-starter-carton-outer","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-ors-maintenance-kit-label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL radicava-ors-maintenance-carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a 26-week carcinogenicity study in male and female transgenic (Tg rasH2) mice, oral administration of edaravone (0 [water control], 0 [vehicle control], 100, 150, or 350 mg/kg) resulted in no increase in tumors. In a 2-year carcinogenicity study in rats, oral administration of edaravone (0, 50, 100, or 200 mg/kg in males; 0, 50, 100, or 250 mg/kg in females) resulted in no increase in tumors. Carcinogenicity studies of edaravone using the intravenous route have not been conducted. Mutagenesis Edaravone was negative in in vitro (bacterial reverse mutation and Chinese hamster lung chromosomal aberration) and in vivo (mouse micronucleus) assays. Impairment of Fertility Intravenous administration of edaravone (0, 3, 20, or 200 mg/kg) prior to and throughout mating in male and female rats and continuing in females to gestation day 7 had no effect on fertility; however, disruption of the estrus cycle and mating behavior was observed at the highest dose tested. No effects on reproductive function were observed at the lower doses, which are up to approximately 3 times the RHD for RADICAVA (60 mg) on a body surface area (mg/m 2 ) basis. Fertility studies of edaravone using the oral route have not been conducted."]},"tags":[{"label":"edaravone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N07XX14","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Amyotrophic lateral sclerosis","category":"indication"},{"label":"Ischemic stroke","category":"indication"},{"label":"Kk Bcj-94","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Antioxidants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Free Radical Scavengers","category":"pharmacology"},{"label":"Neuroprotective Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CEREBRAL INFARCTION","source":"FDA FAERS","actionTaken":"95 reports"},{"date":"","signal":"AMYOTROPHIC LATERAL SCLEROSIS","source":"FDA FAERS","actionTaken":"66 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"39 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"33 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"30 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"29 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"PNEUMONIA ASPIRATION","source":"FDA FAERS","actionTaken":"24 reports"}],"commonSideEffects":[{"effect":"Contusion","drugRate":"15","_validated":true,"placeboRate":"9"},{"effect":"Gait disturbance","drugRate":"13","_validated":true,"placeboRate":"9"},{"effect":"Headache","drugRate":"10","_validated":true,"placeboRate":"6"},{"effect":"Dermatitis","drugRate":"8","_validated":true,"placeboRate":"5"},{"effect":"Eczema","drugRate":"7","_validated":true,"placeboRate":"4"},{"effect":"Respiratory failure, respiratory disorder, hypoxia","drugRate":"6","_validated":true,"placeboRate":"4"},{"effect":"Glycosuria","drugRate":"4","_validated":true,"placeboRate":"2"},{"effect":"Tinea infection","drugRate":"4","_validated":true,"placeboRate":"2"}],"specialPopulations":{"Lactation":"There are no data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Edaravone and its metabolites are excreted in the milk of lactating rats. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for RADICAVA and any potential adverse effects on the breastfed infant from RADICAVA or from the underlying maternal condition.","Pregnancy":"There are no adequate data on the developmental risk associated with the use of RADICAVA in pregnant women. In animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. Most of these effects occurred at doses that were also associated with maternal toxicity (see Animal Data).","Geriatric use":"Of the 184 patients with ALS who received RADICAVA in placebo-controlled clinical trials, total of 53 patients were 65 years of age and older, including patients 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"Safety and effectiveness of RADICAVA in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Kk Bcj-94","patents":[{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2041","useCode":"U-4111","territory":"US","drugProduct":false,"patentNumber":"12310946","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2041","useCode":"U-4111","territory":"US","drugProduct":false,"patentNumber":"12527769","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2041","useCode":"U-4111","territory":"US","drugProduct":false,"patentNumber":"12194025","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 1, 2039","useCode":"U-3468","territory":"US","drugProduct":false,"patentNumber":"11478450","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2041","useCode":"U-4111","territory":"US","drugProduct":false,"patentNumber":"12478611","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 1, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10987341","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 1, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12285409","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 1, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11241416","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 1, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11957660","drugSubstance":false},{"applNo":"N215446","source":"FDA Orange Book","status":"Active","expires":"Nov 1, 2039","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11826352","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EDARAVONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:22:45.619636+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:22:45.619544+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:22:51.810406+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:22:44.001139+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EDARAVONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:22:52.240736+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:42.914963+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:42.914986+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:22:53.702623+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:57.627580+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL290916/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:52.958610+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • Sulfite Allergic Reactions [see Warnings and Precautions (5.2) ] Most common adverse reactions (at least 10% of patients treated with RADICAVA and greater than placebo) are contusion, gait disturbance, and headache ( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:15.383018+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA209176, NDA215446","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:22:42.914990+00:00"}},"allNames":"radicava","offLabel":[],"synonyms":["radicava","edaravone","edarabone","methylphenylpyrazolone","norantipyrine","norphenazone","radicut"],"timeline":[{"date":"2001-04-04","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Mitsubishi Tanabe Pharma Corporation)"},{"date":"2017-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC to Kk Bcj-94"},{"date":"2017-05-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Mitsubishi Tanabe Pharma Development America Inc)"},{"date":"2024-12-23","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 6 manufacturers approved"},{"date":"2029-05-12","type":"negative","source":"FDA Orange Book","milestone":"ODE-144 exclusivity expires"}],"approvals":[{"date":"2001-04-04","orphan":false,"company":"Mitsubishi Tanabe Pharma Corporation","regulator":"PMDA"},{"date":"2017-05-05","orphan":true,"company":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","regulator":"FDA"}],"brandName":"Radicava","ecosystem":[{"indication":"Amyotrophic lateral sclerosis","otherDrugs":[{"name":"phenylbutanoic acid","slug":"phenylbutanoic-acid","company":"Hyperion Theraps Inc"},{"name":"riluzole","slug":"riluzole","company":"Covis Pharma Sarl"},{"name":"taurursodiol","slug":"taurursodiol","company":"Amylyx"},{"name":"tofersen","slug":"tofersen","company":"Biogen Ma"}],"globalPrevalence":308000},{"indication":"Ischemic stroke","otherDrugs":[{"name":"alteplase","slug":"alteplase","company":"Genentech"},{"name":"edoxaban","slug":"edoxaban","company":"Daiichi Sankyo"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"edaravone","explanation":"The mechanism by which RADICAVA exerts its therapeutic effect in patients with ALS is unknown.","oneSentence":"Radicava works by scavenging free radicals and reducing oxidative stress in the body.","technicalDetail":"Edaravone is a free radical scavenger that inhibits the activity of superoxide dismutase 1 (SOD1), a protein involved in the production of reactive oxygen species (ROS). By reducing ROS levels, edaravone decreases oxidative stress and inflammation, which can contribute to the progression of ALS and ischemic stroke."},"commercial":{"launchDate":"2017","_launchSource":"DrugCentral (FDA 2017-05-05, MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4156","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EDARAVONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EDARAVONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:55:55.443962","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:23:16.328717+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"riluzole","drugSlug":"riluzole","fdaApproval":"1995-12-12","patentExpiry":"Mar 12, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sodium oxybate","drugSlug":"sodium-oxybate","fdaApproval":"2002-07-17","patentExpiry":"Sep 15, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"amifampridine","drugSlug":"amifampridine","fdaApproval":"2018-11-28","patentExpiry":"May 26, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tetrabenazine","drugSlug":"tetrabenazine","fdaApproval":"2008-08-15","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fampridine","drugSlug":"fampridine","fdaApproval":"2010-01-22","relationship":"same-class"},{"drugName":"tafamidis","drugSlug":"tafamidis","fdaApproval":"2019-03-05","patentExpiry":"Dec 19, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pitolisant","drugSlug":"pitolisant","fdaApproval":"2019-08-14","patentExpiry":"Sep 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"patisiran","drugSlug":"patisiran","fdaApproval":"2018-10-08","patentExpiry":"Oct 3, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"valbenazine","drugSlug":"valbenazine","fdaApproval":"2017-04-11","patentExpiry":"Sep 18, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"inotersen ","drugSlug":"inotersen-","fdaApproval":"2018-10-05","patentExpiry":"Apr 29, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"deutetrabenazine","drugSlug":"deutetrabenazine","fdaApproval":"2017-04-03","patentExpiry":"Sep 7, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vutrisiran","drugSlug":"vutrisiran","fdaApproval":"2022-06-13","patentExpiry":"Nov 16, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dextromethorphan","drugSlug":"dextromethorphan","fdaApproval":"1957-12-03","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"exclusivity":[{"code":"ODE-144","date":"May 12, 2029"}],"genericName":"edaravone","indications":{"approved":[{"name":"Amyotrophic lateral sclerosis","source":"DrugCentral","snomedId":86044005,"regulator":"FDA","eligibility":"No specific patient eligibility criteria are mentioned in the provided text.","prevalenceClass":"1-9 / 100 000","globalPrevalence":308000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (21665992[PMID])"},{"name":"Ischemic stroke","source":"DrugCentral","snomedId":422504002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Kk Bcj-94","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"riluzole","brandName":"riluzole","genericName":"riluzole","approvalYear":"1995","relationship":"same-class"},{"drugId":"sodium-oxybate","brandName":"sodium oxybate","genericName":"sodium oxybate","approvalYear":"2002","relationship":"same-class"},{"drugId":"amifampridine","brandName":"amifampridine","genericName":"amifampridine","approvalYear":"2018","relationship":"same-class"},{"drugId":"tetrabenazine","brandName":"tetrabenazine","genericName":"tetrabenazine","approvalYear":"2008","relationship":"same-class"},{"drugId":"fampridine","brandName":"fampridine","genericName":"fampridine","approvalYear":"2010","relationship":"same-class"},{"drugId":"tafamidis","brandName":"tafamidis","genericName":"tafamidis","approvalYear":"2019","relationship":"same-class"},{"drugId":"pitolisant","brandName":"pitolisant","genericName":"pitolisant","approvalYear":"2019","relationship":"same-class"},{"drugId":"patisiran","brandName":"patisiran","genericName":"patisiran","approvalYear":"2018","relationship":"same-class"},{"drugId":"valbenazine","brandName":"valbenazine","genericName":"valbenazine","approvalYear":"2017","relationship":"same-class"},{"drugId":"inotersen-","brandName":"inotersen ","genericName":"inotersen ","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04029090","phase":"PHASE1","title":"A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-09-18","conditions":["Healthy Adult Subjects"],"enrollment":27,"completionDate":"2018-10-23"},{"nctId":"NCT07467746","phase":"PHASE2","title":"Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-04","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":84,"completionDate":"2027-04"},{"nctId":"NCT07454473","phase":"PHASE4","title":"Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study","status":"RECRUITING","sponsor":"Chuansheng Zhao","startDate":"2026-03-02","conditions":["Chemo Brain"],"enrollment":80,"completionDate":"2027-12-31"},{"nctId":"NCT03289208","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-10-27","conditions":["Renal Impairment","Healthy"],"enrollment":30,"completionDate":"2018-04-20"},{"nctId":"NCT03664544","phase":"PHASE1","title":"PK Study in Subjects With Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-11-06","conditions":["Severe Hepatic Impairment","Healthy"],"enrollment":12,"completionDate":"2019-03-25"},{"nctId":"NCT00821821","phase":"PHASE2","title":"Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-02","conditions":["Acute Ischemic Stroke (AIS)"],"enrollment":36,"completionDate":"2010-11"},{"nctId":"NCT03346538","phase":"PHASE2","title":"Dose Finding Study of MCI-186 in Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-11-17","conditions":["Acute Ischemic Stroke"],"enrollment":17,"completionDate":"2018-05-14"},{"nctId":"NCT03289234","phase":"PHASE1","title":"Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11-16","conditions":["Hepatic Impairment","Healthy"],"enrollment":22,"completionDate":"2018-07-24"},{"nctId":"NCT00200356","phase":"PHASE4","title":"Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-08","conditions":["Cerebral Infarction"],"enrollment":401,"completionDate":"2006-10"},{"nctId":"NCT04481750","phase":"PHASE1","title":"Study of Oral Edaravone in Healthy Adult Males","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-20","conditions":["Healthy Adult Subjects"],"enrollment":74,"completionDate":"2018-08-03"},{"nctId":"NCT04776135","phase":"PHASE1","title":"Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2021-02-26","conditions":["Healthy Adult Subjects"],"enrollment":36,"completionDate":"2021-04-16"},{"nctId":"NCT05342597","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-06-10","conditions":["Healthy Adult Subjects"],"enrollment":16,"completionDate":"2019-07-24"},{"nctId":"NCT04176224","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-17","conditions":["Japanese Patients With ALS"],"enrollment":9,"completionDate":"2019-09-04"},{"nctId":"NCT04254913","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2020-01-24","conditions":["Japanese Patients With ALS"],"enrollment":6,"completionDate":"2020-04-22"},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":["Healthy Adult Subjects"],"enrollment":84,"completionDate":"2019-01-08"},{"nctId":"NCT04493281","phase":"PHASE1","title":"Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-03-22","conditions":["Healthy Adult Subjects"],"enrollment":42,"completionDate":"2019-05-09"},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":137,"completionDate":"2014-10"},{"nctId":"NCT00424463","phase":"PHASE3","title":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-01","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":181,"completionDate":"2009-05"},{"nctId":"NCT00330681","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-05","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":206,"completionDate":"2008-09"},{"nctId":"NCT00415519","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":25,"completionDate":"2008-07"},{"nctId":"NCT04165824","phase":"PHASE3","title":"Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-11-18","conditions":["ALS"],"enrollment":185,"completionDate":"2021-10-07"},{"nctId":"NCT05568615","phase":"PHASE3","title":"Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2022-10-26","conditions":["ALS"],"enrollment":15,"completionDate":"2023-06-27"},{"nctId":"NCT04577404","phase":"PHASE3","title":"Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-10-29","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":124,"completionDate":"2023-08-09"},{"nctId":"NCT05151471","phase":"PHASE3","title":"Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2022-01-11","conditions":["ALS"],"enrollment":202,"completionDate":"2023-09-29"},{"nctId":"NCT04569084","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-11-13","conditions":["ALS"],"enrollment":384,"completionDate":"2023-09-29"},{"nctId":"NCT06674460","phase":"PHASE3","title":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08-01","conditions":["Cerebral Small Vessel Disease","Ischemic Stroke"],"enrollment":600,"completionDate":"2028-10-01"},{"nctId":"NCT06315231","phase":"PHASE2","title":"Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients","status":"RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-04-08","conditions":["Post-stroke Cognitive Impairment"],"enrollment":226,"completionDate":"2026-12-30"},{"nctId":"NCT07138014","phase":"PHASE2","title":"FHND1002 for ALS Treatment: Phase 2","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2025-10-01","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":180,"completionDate":"2028-03-01"},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":["Ischemic Stroke"],"enrollment":300,"completionDate":"2027-07-31"},{"nctId":"NCT07091994","phase":"PHASE4","title":"A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-08-01","conditions":["Ischemic Stroke, Acute","Active Malignancies"],"enrollment":144,"completionDate":"2026-12-31"},{"nctId":"NCT04097158","phase":"","title":"Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone","status":"RECRUITING","sponsor":"Loma Linda University","startDate":"2019-10-08","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":160,"completionDate":"2026-04"},{"nctId":"NCT05323812","phase":"PHASE2","title":"ASURE: Alzheimer Study Using oRal Edaravone","status":"COMPLETED","sponsor":"Treeway B.V.","startDate":"2023-03-01","conditions":["Alzheimer Disease"],"enrollment":61,"completionDate":"2024-12-30"},{"nctId":"NCT05178810","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2021-10-18","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":313,"completionDate":"2023-10-26"},{"nctId":"NCT05540262","phase":"NA","title":"Edaravone in the Treatment of Optic Neuritis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2022-01-15","conditions":["Optic Neuritis"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":["Healthy Adult Subjects"],"enrollment":72,"completionDate":"2021-01-08"},{"nctId":"NCT06645522","phase":"PHASE4","title":"Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Yi Yang","startDate":"2024-10-30","conditions":["Acute Ischemic Stroke"],"enrollment":1200,"completionDate":"2027-01-30"},{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":["Healthy Adult Subjects"],"enrollment":29,"completionDate":"2023-12-14"},{"nctId":"NCT05086874","phase":"","title":"Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients","status":"COMPLETED","sponsor":"Xin Huang","startDate":"2022-05-07","conditions":["Stroke","Cerebral Infarction","Brain Infarction","Brain Ischemia","Nervous System Diseases","Central Nervous System Diseases","Vascular Diseases","Cardiovascular Diseases"],"enrollment":81292,"completionDate":"2023-03-01"},{"nctId":"NCT04984577","phase":"PHASE2","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"SUSPENDED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-11-15","conditions":["Acute Ischemic Stroke"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT06248242","phase":"PHASE4","title":"Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol","status":"UNKNOWN","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2021-06-01","conditions":["Acute Ischemic Stroke"],"enrollment":400,"completionDate":"2024-06-30"},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":["Subjects With Acute Ischemic Stroke"],"enrollment":880,"completionDate":"2025-05-30"},{"nctId":"NCT04202549","phase":"NA","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2019-12-15","conditions":["Ischemic Stroke"],"enrollment":30,"completionDate":"2022-09-20"},{"nctId":"NCT05644223","phase":"","title":"Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-01-01","conditions":["Acute Ischemic Stroke"],"enrollment":4750,"completionDate":"2024-06-30"},{"nctId":"NCT04259255","phase":"","title":"Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)","status":"UNKNOWN","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-10-21","conditions":["Amyotrophic Lateral Sclerosis","ALS"],"enrollment":300,"completionDate":"2024-03"},{"nctId":"NCT05121883","phase":"","title":"Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-11-01","conditions":["Stroke"],"enrollment":200,"completionDate":"2024-01-31"},{"nctId":"NCT05249920","phase":"PHASE3","title":"Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-03-18","conditions":["Acute Ischemic Stroke","Mechanical Thrombectomy","Edaravone Dexborneol","Phase III"],"enrollment":1362,"completionDate":"2023-05-19"},{"nctId":"NCT04950920","phase":"PHASE3","title":"Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2021-06-28","conditions":["Stroke"],"enrollment":914,"completionDate":"2022-11-14"},{"nctId":"NCT05953103","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-07-03","conditions":["Subjects With Cerebral Hemorrhage"],"enrollment":380,"completionDate":"2025-06-30"},{"nctId":"NCT05920902","phase":"","title":"Arterial Spin Label Depicted Ischemic Stroke Cohort (ASLIS)","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-10-01","conditions":["Acute Ischemic Stroke"],"enrollment":200,"completionDate":"2024-12-31"},{"nctId":"NCT05885919","phase":"PHASE3","title":"Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-01","conditions":["Ischemic Stroke, Acute","Treatment Outcome"],"enrollment":212,"completionDate":"2024-12-31"},{"nctId":"NCT04667637","phase":"PHASE2","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2021-02-23","conditions":["Stroke","Endovascular Thrombectomy"],"enrollment":200,"completionDate":"2022-10-10"},{"nctId":"NCT04817527","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-10-01","conditions":["Stroke, Ischemic"],"enrollment":200,"completionDate":"2022-12-31"},{"nctId":"NCT05024526","phase":"NA","title":"Protective Effects of Edaravone Dexborneol","status":"UNKNOWN","sponsor":"Lili Cao","startDate":"2021-04-01","conditions":["Acute Ischemic Stroke"],"enrollment":80,"completionDate":"2023-03-31"},{"nctId":"NCT05035953","phase":"PHASE2","title":"Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-09-13","conditions":["Stroke, Ischemic"],"enrollment":200,"completionDate":"2024-03-13"},{"nctId":"NCT04219865","phase":"PHASE1","title":"Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-06-05","conditions":["Pharmacokinetics"],"enrollment":40,"completionDate":"2019-08-16"},{"nctId":"NCT04218513","phase":"PHASE1","title":"Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-05-10","conditions":["Drug-drug Interaction"],"enrollment":24,"completionDate":"2019-05-31"},{"nctId":"NCT04714177","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-03-01","conditions":["Intracerebral Hemorrhage"],"enrollment":390,"completionDate":"2023-09-01"},{"nctId":"NCT03968042","phase":"PHASE2","title":"Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-06-30","conditions":["Alcohol-induced Brain Injury"],"enrollment":150,"completionDate":"2021-12"},{"nctId":"NCT04391361","phase":"PHASE2","title":"The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-11-01","conditions":["Amyotrophic Lateral Sclerosis","Respiratory Function","Scopolamine"],"enrollment":30,"completionDate":"2023-10-31"},{"nctId":"NCT03495206","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet","status":"UNKNOWN","sponsor":"Yantai YenePharma Co., Ltd.","startDate":"2018-10-25","conditions":["Stroke, Acute","Intracranial Hemorrhages"],"enrollment":24,"completionDate":"2021-02"},{"nctId":"NCT03272802","phase":"PHASE2,PHASE3","title":"Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-03-16","conditions":["Neuromuscular Diseases"],"enrollment":20,"completionDate":"2019-09-16"},{"nctId":"NCT02430350","phase":"PHASE3","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2015-05","conditions":["Acute Ischemic Stroke"],"enrollment":1200,"completionDate":"2016-12"},{"nctId":"NCT02644915","phase":"NA","title":"Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-03","conditions":["Kidney Transplantation"],"enrollment":150,"completionDate":"2016-10"},{"nctId":"NCT01929096","phase":"PHASE2","title":"Compound Edaravone Injection for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":["Acute Ischemic Stroke"],"enrollment":400,"completionDate":"2015-02"},{"nctId":"NCT00265239","phase":"PHASE4","title":"Pilot Study of Edaravone to Treat Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2001-04","conditions":["Myocardial Infarction","Reperfusion Injury"],"enrollment":104,"completionDate":"2007-06"},{"nctId":"NCT01894334","phase":"NA","title":"Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-04","conditions":["Acute Aortic Dissection"],"enrollment":220,"completionDate":"2015-01"},{"nctId":"NCT01865201","phase":"PHASE2","title":"Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2009-03","conditions":["Nasopharyngeal Carcinoma","Brain Necrosis"],"enrollment":154,"completionDate":"2012-09"},{"nctId":"NCT01556854","phase":"","title":"Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"yongjun wang","startDate":"2011-07","conditions":["Acute Ischemic Stroke"],"enrollment":20000,"completionDate":"2014-06"},{"nctId":"NCT01518231","phase":"PHASE1","title":"Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke","status":"UNKNOWN","sponsor":"Zhejiang Hospital","startDate":"2012-01","conditions":["Stroke"],"enrollment":40,"completionDate":"2013-12"},{"nctId":"NCT00153946","phase":"PHASE4","title":"Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Combination Therapy for Acute Ischemic Stroke Study Group","startDate":"2004-08","conditions":["Stroke"],"enrollment":814,"completionDate":"2008-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"RADICAVA"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"257218","NDDF":"017212","UNII":"S798V6YJRP","CHEBI":"CHEBI:31530","VANDF":"4036711","INN_ID":"7362","RXNORM":"1921877","UMLSCUI":"C0070694","chemblId":"CHEMBL290916","ChEMBL_ID":"CHEMBL290916","KEGG_DRUG":"D01552","DRUGBANK_ID":"DB12243","PDB_CHEM_ID":"W1P","PUBCHEM_CID":"4021","SNOMEDCT_US":"736496005","IUPHAR_LIGAND_ID":"11994","MESH_DESCRIPTOR_UI":"D000077553"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVENOUS","company":"Mitsubishi Tanabe Pharma America, Inc.","brandName":"RADICAVA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2017-","companyName":"Mitsubishi Tanabe Pharma Development America Inc","relationship":"Original Developer"},{"period":"present","companyName":"Kk Bcj-94","relationship":"Current Owner"},{"period":"2001","companyName":"Mitsubishi Tanabe Pharma Corporation","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.36 hours","clearance":"1.42 mL/min/kg","fractionUnbound":"0.89%","volumeOfDistribution":"0.23 L/kg"},"publicationCount":1759,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"N07XX14","allCodes":["N07XX14"]},"biosimilarFilings":[],"originalDeveloper":"Mitsubishi Tanabe Pharma Development America Inc","recentPublications":[{"date":"2026 Mar 27","pmid":"41889240","title":"Strophioglanes A-E and (±)-Trigoxyphin K, ent-Cleistanthane Diterpenoids from Strophioblachia glandulosa var. cordifolia.","journal":"Journal of natural products"},{"date":"2026 Mar 20","pmid":"41866101","title":"Ropivacaine attenuates cerebral ischemia-reperfusion injury in young male mice by reducing endothelial oxidative stress through activation of the Htr7/cAMP-PKA signaling.","journal":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association"},{"date":"2025 Nov 11","pmid":"41839581","title":"[Effects of acupuncture on ferroptosis and ferritinophagy in cerebral ischemia-reperfusion rats based on KAT3B/ACSL4 pathway].","journal":"Zhen ci yan jiu = Acupuncture research"},{"date":"2026 Mar 14","pmid":"41832246","title":"Trial of Edaravone for severe hypoxic ischemic encephalopathy in adults: a double-blind placebo-controlled study.","journal":"Journal of neurology"},{"date":"2026 Mar 14","pmid":"41830523","title":"Correction to \"Generalizability of Edaravone Efficacy\".","journal":"Muscle & nerve"}],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Dr Reddys","Gland","Hikma","Long Grove Pharms","Pharmobedient","Sandoz"],"status":"approved","companyName":"Kk Bcj-94","companyId":"kk-bcj-94","modality":"Small molecule","firstApprovalDate":"2017","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2001-04-04T00:00:00.000Z","mah":"Mitsubishi Tanabe Pharma Corporation","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2017-05-05T00:00:00.000Z","mah":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2017-05-05T00:00:00.000Z","mah":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2017-05-05T00:00:00.000Z","mah":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2017-05-05T00:00:00.000Z","mah":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2017-05-05T00:00:00.000Z","mah":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-05-05T00:00:00.000Z","mah":"MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-12T00:00:00.000Z","mah":"SHIONOGI","brand_name_local":null,"application_number":"NDA215446"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-11-18T00:00:00.000Z","mah":"SHIONOGI","brand_name_local":null,"application_number":"NDA209176"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-05-06T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA216199"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-10-31T00:00:00.000Z","mah":"PHARMOBEDIENT","brand_name_local":null,"application_number":"ANDA217565"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-12-23T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":"ANDA216902"},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:23:16.328717+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}